The NFL will spend up to $1 million funding up to five studies that will examine how to better help players ease their pain and find alternatives to opioids.
Among those potential alternatives: marijuana and other cannabis-derived products.
The league announced its call for research proposals Tuesday. The league and the NFL Players Association formed a joint pain management committee in 2019 to help find alternatives to opioids and give players and league medical staffs information on pain management.
Dr. Allen Sills, the NFL's chief medical officer, said there are a lot of great ideas and important research that need to be funded.
“This is really not an NFL issue or a sports issue,” Sills said. "This is a societal issue, which is how can we better understand and treat pain and what are the alternatives that may be out there for treatment in addition to opioids which have long been used.”
Some retired NFL players, including Nate Jackson and Kyle Turley, have spoken out about their use of marijuana during their time in the league and said it's a better way of managing pain than the drugs prescribed by team doctors. The league prohibits marijuana use by players.
Jeff Miller, the NFL’s executive vice president overseeing player health and safety, said the league’s policy on substance abuse is not changing, with Tuesday’s announcement focused only on proposals and research.
The pain management committee held two forums in 2020 to learn more about cannabidiol science and manufacturing and now wants more information on how cannabinoids not only affect pain but the performance of NFL players.
Dr. Kevin Hill is co-chairman of the joint pain management committee and wrote a book titled “Marijuana: The Unbiased Truth about the World's Most Popular Weed." He said players have been asking about cannabis and cannabidiol CBD. Hill said they've tried to provide the best information on a controversial topic.
“Unfortunately, the level of interest right now far exceeds the level of evidence supporting the use of medical cannabis for pain,” Hill said.
Hill, also director of addiction psychiatry at Beth Israel Deaconess Medical Center and associate professor of psychiatry at Harvard Medical School, said there are flaws in each of the controlled trials despite some evidence supporting the use of medical cannabis for pain.
“That’s why we put out this request for proposals so that we can collectively with the PA, the players association, move towards finding better treatments for pain. Those treatments may include cannabis, and they may include CBD,” Hill said.
The NFL opened the application process Tuesday. The league wants initial proposals studying how cannabinoids can help players manage pain daily and after surgery, how cannabis or cannabinoids affect players' athletic performance, and how other non-pharmaceutical treatments can benefit players.
Proposals must be submitted by July 31 with the pain management committee paring down submissions for formal presentations. Those will presented in November with a final decision the week of Dec. 6.
It’s no secret that the world is amidst a climate crisis never before seen in our time. And our excessive resource consumption is to blame. But just exactly what resources are to blame might surprise you. Hint: fossil fuels are only one part of the problem.
Dr. Robert Lahita, the director of Saint Joseph's Institute for Autoimmune and Rheumatic Diseases, joined Cheddar to discuss the latest on omicron as the new variant has popped up in more than a dozen states so far. He emphasized that vaccinations should remain the priority despite efficacy against the new variant being unknown at this point.
Six states have confirmed cases of the new Omicron coronavirus variant, and this number is expected to grow. Cheddar's Hena Doba speaks with Dr. William Schaffner,
Professor of Preventive Medicine at Vanderbilt University Medical Center, on the latest developments.
Just days after the detection of the Omicron variant, the World Health Organization has agreed to start the process of establishing a global pandemic treaty or accord. Amy Maxmen, senior reporter for Nature, and Dr. Samuel Scarpino, managing director for the Rockefeller Foundation's Pandemic Prevention Institute, joined Cheddar to discuss this effort and what lessons can be learned from the many COVID-19 failures as the world prepares for future pandemics.
Local Bounti rang the opening bell December 3 in honor of its recent trading debut on the NYSE after closing a $1.1 billion SPAC deal. The company operates an indoor growing facility in Montana and aims to transform the production and delivery of local, fresh and sustainably-grown leafy greens. Craig Hurlbert, co-founder and co-CEO of Local Bounti, joined Cheddar to discuss the company's goals as a newly publicly-traded company.
Stephan Winkelmann, president of Bugatti Automobiles and CEO of Lamborghini, stopped by Cheddar to talk about Lamborghini's 2021 success after the luxury automaker set a company sales record on more than 6,9000 vehicles delivered. With climate change top of mind for the auto industry, Winkelmann also talked about Lamborghini's commitment to hybridizing its entire fleet. Still, when it comes to supercars, the legacy brand isn't quite ready to give up gasoline power, and according to the CEO, three new combustion engine vehicles will be available in 2022.
New York officials have confirmed five omicron COVID-19 cases in New York City and on Long Island after a Minnesota man who tested positive for the same variant said he attended a convention in November at the Jacob Javits Center in Manhattan.
It's Friday at long last. Jill and Carlo cover the latest on Omicron, including a possible superspreader event in NYC. Plus, previewing the November jobs report, a new Zoom feature no one asked for, and when it's no longer a good idea to eat Thanksgiving leftovers.
Three cases of the new omicron COVID-19 variant have been confirmed in the U.S. Cheddar speaks with global infection disease specialist Dr. Rajeev Fernando on how to prepare for a possible new coronavirus wave.
